CO6180466A2 - Composiciones y metodos para diagnosticar y tratar cancer - Google Patents

Composiciones y metodos para diagnosticar y tratar cancer

Info

Publication number
CO6180466A2
CO6180466A2 CO09031240A CO09031240A CO6180466A2 CO 6180466 A2 CO6180466 A2 CO 6180466A2 CO 09031240 A CO09031240 A CO 09031240A CO 09031240 A CO09031240 A CO 09031240A CO 6180466 A2 CO6180466 A2 CO 6180466A2
Authority
CO
Colombia
Prior art keywords
human dll4
antibody according
isolated antibody
amino acids
terminal region
Prior art date
Application number
CO09031240A
Other languages
English (en)
Inventor
Austin Gurney
Timothy Honey
Sanjeev H Satyal
Fumiko Axelrod
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of CO6180466A2 publication Critical patent/CO6180466A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

1.- Anticuerpo aislado que se une específicamente a un epítopo de DLL4 humano que comprende los aminoácidos dentro de la región N-terminal de DLL4 humano (SEQ ID NO: 27), el anticuerpo está caracterizado porque afecta el crecimiento de un tumor que comprende células madre de cáncer. 2.- Anticuerpo aislado de conformidad con la reivindicación 1, caracterizado porque el epítopo de DLL4 humano se forma por una combinación de la región N-terminal de DLL4 humano (SEQ ID NO: 27) y DSL de DLL4 humano (SEQ ID NO: 26). 3.- Anticuerpo aislado de conformidad con la reivindicación 1, caracterizado porque el epítopo de DLL4 humano comprende además aminoácidos dentro del DSL de DLL4 humano (SEQ ID NO: 26). 4.- Anticuerpo aislado de conformidad con la reivindicación 2, caracterizado porque el epítopo de DLL4 humano comprende los aminoácidos 66-73 (QAVVSPGP) de la región N-terminal de DLL4 humano. 5.- Anticuerpo aislado de conformidad con la reivindicación 4, caracterizado porque el epítopo de DLL4 humano comprende los aminoácidos V68, V69 y P71 de la región N-terminal de DLL4 humano. 6.- Anticuerpo aislado de conformidad con la reivindicación 2, caracterizado porque el epítopo de DLL4 humano comprende los aminoácidos 139-146 (LISKIAIQ) de la región N-terminal de DLL4 humano. 7.- Anticuerpo aislado de conformidad con la reivindicación 6, caracterizado porque el epítopo de DLL4 humano comprende los aminoácidos K142 y A144 de la región N-terminal de DLL4 humano. 8.- Anticuerpo aislado de conformidad con la reivindicación 2, caracterizado porque el epítopo de DLL4 humano comprende los aminoácidos 66-73 (KAVVSPGP) y 139-146 (LISKIAIQ) de la región N-terminal de DLL4 humano. 9.- Anticuerpo aislado de conformidad con la reivindicación 8, caracterizado porque el epítopo de DLL4 humano comprende los aminoácidos V68, V69, P71, K142 y K144 de la región N-terminal de DLL4 humano. 10.- Anticuerpo aislado de conformidad con cualquiera de las reivindicaciones anteriores, caracterizado porque la afección es una reducción en el volumen de tumor. 11.- Anticuerpo de conformidad con cualquiera de las reivindicaciones 1 a 9, caracterizado porque es un anticuerpo monoclonal.
CO09031240A 2006-09-29 2009-03-26 Composiciones y metodos para diagnosticar y tratar cancer CO6180466A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84790406P 2006-09-29 2006-09-29
US88626007P 2007-01-23 2007-01-23
US94254207P 2007-06-07 2007-06-07

Publications (1)

Publication Number Publication Date
CO6180466A2 true CO6180466A2 (es) 2010-07-19

Family

ID=39268983

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09031240A CO6180466A2 (es) 2006-09-29 2009-03-26 Composiciones y metodos para diagnosticar y tratar cancer

Country Status (28)

Country Link
US (5) US7750124B2 (es)
EP (3) EP3357932A1 (es)
JP (3) JP5535633B2 (es)
KR (1) KR101477824B1 (es)
AU (1) AU2007305443B2 (es)
BR (1) BRPI0717431A2 (es)
CA (1) CA2664738C (es)
CO (1) CO6180466A2 (es)
CR (1) CR10667A (es)
CY (1) CY1117154T1 (es)
DK (1) DK2066694T3 (es)
EA (1) EA018260B1 (es)
ES (1) ES2557953T3 (es)
HK (1) HK1133268A1 (es)
HR (1) HRP20160082T1 (es)
HU (1) HUE028379T2 (es)
IL (1) IL197721A (es)
MA (1) MA30808B1 (es)
ME (1) ME02371B (es)
MX (1) MX2009003229A (es)
NO (1) NO20091635L (es)
NZ (1) NZ576404A (es)
PL (1) PL2066694T3 (es)
PT (1) PT2066694E (es)
RS (1) RS54452B1 (es)
SI (1) SI2066694T1 (es)
WO (1) WO2008042236A2 (es)
ZA (1) ZA200901615B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP3357932A1 (en) 2006-09-29 2018-08-08 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
US8158757B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2009148575A1 (en) * 2008-05-30 2009-12-10 Xbiotech, Inc. Interleukin-1 alpha abs and methods of use
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
CA2729949A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
PL2307459T3 (pl) 2008-07-08 2015-05-29 Oncomed Pharm Inc Czynniki wiążące receptor Notch1 i sposoby ich stosowania
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
CA2735900A1 (en) * 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
PT2842573T (pt) 2008-11-07 2017-12-04 Galaxy Biotech Llc Anticorpos monoclonais para o recetor 2 do factor de crescimento de fibroblastos
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
EP2424567B1 (en) * 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
MX2012002605A (es) 2009-08-29 2012-04-02 Abbott Lab Proteinas terapeutico de union a dll4.
BR112012004710A2 (pt) 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011063237A2 (en) 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
US20110165162A1 (en) * 2009-12-01 2011-07-07 Oncomed Pharmaceuticals, Inc. Methods for Treating Cancers Comprising K-ras Mutations
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
ES2561102T3 (es) 2010-01-13 2016-02-24 Oncomed Pharmaceuticals, Inc. Agentes de unión a Notch1 y procedimientos de uso de los mismos
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
BR112012021941A2 (pt) * 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013540995A (ja) * 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 疾患に対する循環バイオマーカー
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012068098A1 (en) * 2010-11-15 2012-05-24 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
KR101621036B1 (ko) 2011-03-27 2016-05-13 온코스템 다이아그노틱스 (모리셔스) 프라이빗 리미티드 종양 세포를 동정하기 위한 마커, 그의 방법 및 키트
JP2014523421A (ja) * 2011-06-17 2014-09-11 ハリス，エイドリアン，エル． 抗ｄｌｌ４抗体を使用して腫瘍治療における放射線に対する反応を増大させる方法
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
WO2013039954A1 (en) * 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
ES2707580T3 (es) 2011-09-23 2019-04-04 Oncomed Pharm Inc Agentes de unión a VEGF/DLL4 y usos de los mismos
AU2012362326A1 (en) 2011-12-30 2014-07-24 Abbvie Inc. Dual variable domain immunoglobulins against IL-13 and/or IL-17
WO2014062245A2 (en) 2012-05-31 2014-04-24 Sorrento Therapeutics Inc. Antigen binding proteins that bind dll-4
WO2013184912A2 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
EP2888283B1 (en) 2012-08-24 2018-09-19 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
WO2014062659A2 (en) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Methods of treating ocular diseases
WO2014071018A1 (en) * 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
BR112015013127A2 (pt) 2012-12-04 2017-09-26 Oncomed Pharm Inc imunoterapia com agentes de ligação
JP6449537B2 (ja) * 2012-12-27 2019-01-09 日本メジフィジックス株式会社 抗腫瘍剤、及び、抗腫瘍用キット
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
GB201312727D0 (en) * 2013-07-16 2013-08-28 Isis Innovation Modulators
SI3027651T1 (sl) 2013-08-01 2019-05-31 Five Prime Therapeutics, Inc. Afukozilirana protitelesa proti fgfr2iiib
EP3077546A4 (en) 2013-12-02 2017-04-26 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
WO2015108203A1 (ja) * 2014-01-15 2015-07-23 株式会社オーダーメードメディカルリサーチ 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
IL289475B2 (en) * 2014-07-21 2023-10-01 Delinia Inc Molecules that activate T cells are selectively regulated for the treatment of autoimmune diseases
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3353204B1 (en) * 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
RU2021107536A (ru) 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3457971B1 (en) 2016-05-19 2021-09-29 Santa Anna Tech LLC Catheter with a double balloon structure to generate and apply a heated ablative zone to tissue
US11026996B2 (en) * 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
JP7500195B2 (ja) * 2016-08-23 2024-06-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
BR112019005333A2 (pt) 2016-09-21 2019-06-11 Aptevo Research And Development Llc proteínas de ligação a cd123 e composições e métodos relacionados
SG11201903882VA (en) 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
EP3624837A1 (en) 2017-05-16 2020-03-25 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
AU2019338398A1 (en) 2018-09-11 2021-05-20 Aqua Heart, Inc. Heated vapor ablation systems and methods for treating cardiac conditions
WO2020102644A2 (en) 2018-11-15 2020-05-22 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with vegf/dll4 binding agent
EP4021326A4 (en) 2019-08-28 2023-09-13 Santa Anna Tech LLC SYSTEMS AND PROCEDURES FOR PROSTATE TISSUE ABLATION
WO2023149977A1 (en) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Methods for treating cancer

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2248608B1 (es) * 1973-10-17 1977-05-27 Labo Electronique Physique
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE442373T1 (de) 1995-06-28 2009-09-15 Imp Cancer Res Tech Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
JPH09124697A (ja) * 1995-11-01 1997-05-13 Toagosei Co Ltd ペプチド及びモノクローナル抗体
EP0861894B1 (en) 1995-11-17 2006-03-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6121045A (en) 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
DE69836131T3 (de) 1997-04-04 2017-06-14 Millennium Pharmaceuticals, Inc. Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
US20030180784A1 (en) 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US7365166B2 (en) * 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
EP1325932B9 (en) 1997-04-07 2006-07-19 Genentech, Inc. Anti-vegf antibodies
CA2288343A1 (en) 1997-04-25 1998-11-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
ES2246069T3 (es) * 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP1004669B1 (en) 1997-05-14 2007-04-18 Asahi Kasei Kabushiki Kaisha Novel differentiation inhibitor
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
JP2002523018A (ja) 1998-07-27 2002-07-30 アムジエン・インコーポレーテツド デルタ関連ポリペプチド
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
ATE293164T1 (de) 1999-06-08 2005-04-15 Regeneron Pharma Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
JP2003505082A (ja) 1999-07-26 2003-02-12 ジェネンテック・インコーポレーテッド 新規なポリヌクレオチドとその使用法
CA2492070A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Lung tumor marker pro4329 polypeptides and nucleic acids encoding the same
WO2001077169A2 (en) 2000-04-05 2001-10-18 Kirin Beer Kabushiki Kaisha Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
WO2003011317A1 (en) 2001-07-25 2003-02-13 Lorantis Limited Modulators of notch signalling for use in immunotherapy
JP4689956B2 (ja) * 2001-08-01 2011-06-01 ユニバーシティ オブ ブリストル 増殖因子イソ型
WO2003042246A2 (en) 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
JP2005518785A (ja) * 2001-11-14 2005-06-30 ロランティス リミテッド 内科療法
US20050137130A1 (en) 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
JP2005511754A (ja) * 2001-12-07 2005-04-28 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 乳癌幹細胞の予測的同定および特徴づけ
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
GB0218879D0 (en) 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
AU2003267563A1 (en) 2002-09-10 2004-04-30 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
WO2004110490A2 (en) 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
JP4818917B2 (ja) * 2003-08-08 2011-11-16 イミューノメディクス、インコーポレイテッド 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
EP1753442A2 (en) 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
AU2005265071A1 (en) 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US20080254031A1 (en) 2004-09-09 2008-10-16 Exonhit Therapeutics Sa Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
US8911726B2 (en) * 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
JP2008519829A (ja) 2004-11-10 2008-06-12 ヒュブレヒト ラボラトリウム Ｎｏｔｃｈ経路活性化の阻害による腸腺腫および／または腺癌の処置
EP1812064A4 (en) * 2004-11-19 2009-07-08 Cornell Res Foundation Inc USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
CA2597247A1 (en) 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
EP3479844B1 (en) * 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
JP2008545753A (ja) * 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
US7531172B2 (en) 2005-08-12 2009-05-12 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a VEGF antagonist
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
US20070213266A1 (en) 2005-09-01 2007-09-13 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of Delta-like 4
NZ568739A (en) 2005-12-16 2010-09-30 Regeneron Pharma Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists
US20090221549A1 (en) 2006-02-17 2009-09-03 Gilead Colorado, Inc. Antihypertensive therapy
US7354582B2 (en) * 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
EP2029159A2 (en) * 2006-06-06 2009-03-04 Genentech, Inc. Compositions and methods for modulating vascular development
SG175615A1 (en) 2006-06-06 2011-11-28 Genentech Inc Anti-dll4 antibodies and methods using same
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
SI2054082T1 (sl) 2006-08-07 2013-04-30 Regeneron Pharmaceuticals, Inc. Uporaba DII4 antagonistov pri ishemični poškodbi ali vaskularni insuficienci
WO2008027236A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
EP3357932A1 (en) * 2006-09-29 2018-08-08 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2010507594A (ja) * 2006-10-20 2010-03-11 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
US20100166746A1 (en) 2006-12-04 2010-07-01 Medlmmune Way High potency recombinant antibodies, methods for producing them and use in cancer therapy
RU2482877C2 (ru) * 2006-12-11 2013-05-27 Дженентек, Инк. Композиции и способы для лечения опухоли
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
TW200831538A (en) * 2006-12-19 2008-08-01 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
AU2007338734A1 (en) 2006-12-20 2008-07-03 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
MX2009011898A (es) 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
US8216571B2 (en) * 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
CN101970486A (zh) * 2007-10-25 2011-02-09 布里斯托尔大学 特异于血管内皮生长因子(vegf)的促血管发生同工型的抗体
WO2009075565A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR20110014607A (ko) * 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
UA105198C2 (ru) * 2008-12-12 2014-04-25 Берингер Ингельхайм Интернациональ Гмбх Антитело против инсулиноподобных факторов роста
US20100266589A1 (en) * 2009-04-20 2010-10-21 Eric Hedrick Adjuvant cancer therapy
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP2424567B1 (en) * 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MX2011013455A (es) * 2009-07-08 2012-02-13 Amgen Inc Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
WO2011047442A1 (en) 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
US20110165162A1 (en) * 2009-12-01 2011-07-07 Oncomed Pharmaceuticals, Inc. Methods for Treating Cancers Comprising K-ras Mutations
CA2789446A1 (en) 2010-02-12 2011-08-18 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
WO2012068098A1 (en) 2010-11-15 2012-05-24 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
ES2707580T3 (es) 2011-09-23 2019-04-04 Oncomed Pharm Inc Agentes de unión a VEGF/DLL4 y usos de los mismos
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
WO2014071018A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist

Also Published As

Publication number Publication date
EP2066694A2 (en) 2009-06-10
KR20090078334A (ko) 2009-07-17
EP3357932A1 (en) 2018-08-08
HUE028379T2 (en) 2016-12-28
JP5535633B2 (ja) 2014-07-02
AU2007305443A1 (en) 2008-04-10
EP2066694A4 (en) 2010-05-05
JP2014158469A (ja) 2014-09-04
US20190060453A1 (en) 2019-02-28
NO20091635L (no) 2009-06-26
WO2008042236A3 (en) 2008-07-31
EP2562188A3 (en) 2013-03-06
US9376497B2 (en) 2016-06-28
US20160367667A1 (en) 2016-12-22
US9228020B2 (en) 2016-01-05
US20100316637A1 (en) 2010-12-16
JP2010504755A (ja) 2010-02-18
HRP20160082T1 (hr) 2016-02-26
NZ576404A (en) 2012-02-24
CA2664738A1 (en) 2008-04-10
JP2017002076A (ja) 2017-01-05
CA2664738C (en) 2017-03-07
US20080187532A1 (en) 2008-08-07
ES2557953T3 (es) 2016-01-29
ME02371B (me) 2016-06-20
EP2562188A2 (en) 2013-02-27
RS54452B1 (en) 2016-06-30
BRPI0717431A2 (pt) 2013-11-12
SI2066694T1 (sl) 2016-02-29
CR10667A (es) 2009-05-25
EP2066694B1 (en) 2015-11-04
US20130266569A1 (en) 2013-10-10
KR101477824B1 (ko) 2015-01-02
PT2066694E (pt) 2016-01-27
JP5997194B2 (ja) 2016-09-28
US20140147443A9 (en) 2014-05-29
DK2066694T3 (en) 2016-02-08
HK1133268A1 (en) 2010-03-19
EA200970335A1 (ru) 2009-10-30
US7750124B2 (en) 2010-07-06
WO2008042236A2 (en) 2008-04-10
IL197721A0 (en) 2011-08-01
IL197721A (en) 2015-03-31
ZA200901615B (en) 2009-12-30
EA018260B1 (ru) 2013-06-28
MA30808B1 (fr) 2009-10-01
PL2066694T3 (pl) 2016-04-29
CY1117154T1 (el) 2017-04-05
AU2007305443B2 (en) 2012-08-23
MX2009003229A (es) 2009-06-18

Similar Documents

Publication Publication Date Title
CO6180466A2 (es) Composiciones y metodos para diagnosticar y tratar cancer
ES2667568T3 (es) Anticuerpo anti-B7-H3
CO2020014727A2 (es) Anticuerpo anti proteína reguladora de señales alfa sirpαlfa
AR118047A2 (es) Anticuerpo aislado o fragmento del mismo, composición farmacéutica y molécula biespecífica
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
PA8852901A1 (es) Inhibidores de proteina cinasa
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
CO6160304A2 (es) Composiciones y metodos para el diagnostico y el tratamiento de tumores
CO6251322A2 (es) Polipeptidos dominios variables de anticuerpos y antagonistas
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer
AR054254A1 (es) Terapia adyuvante con trastuzumab (herceptin registrado)
ECSP099276A (es) Agente para prevenir/tratar el cancer
PE20121361A1 (es) Antagonistas de pcsk9
AR091702A1 (es) Anticuerpos anti-cd79b e inmunoconjugados
PE20230415A1 (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SINDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CR20110606A (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
ES2675375T3 (es) Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
CO6180469A2 (es) Anticuerpos anti-epha2
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20120431A1 (es) Anticuerpo antagonista para el tratamiento del cancer
NZ606195A (en) Methods and compositions for liver cancer therapy
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
EA200801735A1 (ru) Антиамилоидные иммуногенные композиции, способы и применения

Legal Events

Date Code Title Description
FG Application granted